Suicide gene-modified killer cells as an allogeneic alternative to autologous cytokine-induced killer cell immunotherapy of hepatocellular carcinoma

TAO WU¹,²,³, CÉLINE LEBOEUF²,³, SARAH DURAND²,³, BIN SU²,³, MARINA DESCHAMPS⁴,⁶, XIAOWEN ZHANG¹, CHRISTOPHE FERRAND⁴,⁶, PATRICK PESSAUX²,³,⁷,⁸ and ERIC ROBINET²,³,⁸

¹Department of Hepatobiliary and Pancreatic Surgery, Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650500, P.R. China; ²French National Institute of Health and Medical Research and ³University of Strasbourg, Research Unit 1110, F-67000 Strasbourg; ⁴French National Institute of Health and Medical Research and ⁵University of Strasbourg, F-25000 Besançon; ⁶Hepatodigestive Pole, New Civil Hospital, University Hospital of Strasbourg; ⁷Institute of Image-Guided Surgery, University Hospital Institute of Strasbourg, F-67000 Strasbourg, France

Received April 21, 2015; Accepted December 15, 2015

DOI: 10.3892/mmr.2016.4811

Abstract. Adoptive immunotherapy using autologous cytokine-induced killer (CIK) cells reduces the recurrence rate of hepatocellular carcinoma (HCC) in association with transarterial chemoembolization or radiofrequency. However, a large-scale development of this immunotherapy remains difficult to consider in an autologous setting, considering the logistical hurdles associated with the production of this cell therapy product. A previous study has provided the in vitro and in vivo proof-of-concept that allogeneic suicide gene-modified killer cells (aSGMKCs) from healthy blood donors (a cell therapy product previously demonstrated to provide anti-leukemic effects to patients receiving allogeneic hematopoietic transplantation) may exert a potent anti-tumor effect towards HCC. Therefore, the development of a bank of ‘ready-for-use’ aSGMKCs was proposed as an approach allowing for the development of immunotherapies that are more convenient and on a broader scale than that of autologous therapies. In the present study, aSGMKCs were compared with CIK cells generated according to three different protocols. Similar to CIK cells, the cytotoxic activity of aSGMKCs toward the Huh-7 HCC cell line was mediated by tumor necrosis factor-related apoptosis-inducing ligand, tumor necrosis factor-α and interferon-γ. Furthermore, the frequency of natural killer (NK), NK-like T and T cells, and their in vitro and in vivo cytotoxicity activities were similar between aSGMKCs and CIK cells. Thus, the present study demonstrated that aSGMKCs are similar to CIK cells, further suggesting the possibility for future use of aSGMKCs in the treatment of solid tumors, including HCC.

Introduction

Hepatocellular carcinoma (HCC) is the second most common cause of cancer-associated mortality worldwide and the leading cause of mortality among cirrhotic patients (1). Early-stage tumors may be curatively treated using surgical approaches; however, they are often undiagnosed and treatment options for advanced HCC, including transarterial chemoembolization (TACE) and radiofrequency ablation (RFA), are unsatisfactory. The multikinase inhibitor sorafenib has been identified to improve the survival benefit for patients with locally advanced or metastatic HCC; however, adverse side effects and moderate efficacy limit its use in patients with advanced liver disease (2). Therefore, it is important to develop a therapy for advanced HCC that is well-tolerated, cost-effective and poses an acceptable risk-to-benefit ratio.

Cytokine-induced killer (CIK) cells, generated by ex vivo expansion of peripheral blood mononuclear cells (PBMCs), have been described as exerting a highly potent, non-major histocompatibility complex (MHC)-restricted, CD3⁺/CD56⁺, natural killer-like T cell-mediated cytotoxic activity in solid tumors (3-6), while exhibiting a low capacity to induce graft-versus-host disease (GvHD) (7,8). Autologous immunotherapy with CIK cells has been evaluated toward different solid tumors, including HCC (9,10), and was demonstrated, in association with TACE and RFA or as adjuvant therapy, to increase median time to progression, progression-free survival and overall survival for post-operative patients (11-14). Randomized studies comparing TACE, RFA and/or surgery with or without autologous immunotherapy using patient-derived CIK cells indicated that immunotherapy...
significantly reduces the recurrence rate of HCC and increases the overall and progression-free survival of patients with HCC (15-18). A previous study performed a meta-analysis and confirmed the benefits of combining CIK immunotherapy with conventional treatments (19). However, a large-scale development of this immunotherapy remains difficult to consider in an autologous setting, due to the logistical hurdles associated with the production of this cell therapy product (CTP). A previous study provided the in vitro and in vivo proof-of-concept that another CTP, termed allogeneic suicide gene-modified killer cells (aSGMKCs), may provide a potent anti-tumor effect toward HCC (20). This CTP has been previously demonstrated to provide an anti-leukemic effect when infused to patients receiving bone marrow transplantation (21), with no major acute toxicity upon infusion. Long-term monitoring of patients demonstrated the safety of this approach (22,23).

In the event of severe side effects, including the induction of GvHD, the prior retroviral vector-mediated transfer of a suicide gene in these cells allows them to be efficiently killed by infusion of a prodrug, leading to an efficient control of possible side effects (24-27). Therefore, the production of a bank of ‘ready-for-use’ aSGMKCs from healthy blood donors was proposed as an innovative approach, to allow for the development of immunotherapies on a more convenient and broader scale than for that of autologous therapies. This approach is more attractive, due to several reasons. Firstly, CTP production is easier to perform when using lymphocytes from normal donors, as they typically expand more efficiently than those from heavily-treated patients (28,29). Additionally, a ‘ready-for-use’ allogeneic CTP may be rapidly infused into the patient, without the time required for the production and qualification of a patient-specific CTP (an autologous or patient-directed CTP) (30). Furthermore, there is no risk of losing a clinical-grade CTP batch; if a cell batch planned to be infused to a given patient is not administered due to medical contra-indication or non-compliance, it may still be used later for another patient (30). Although the gene transfer adds technical complexity during the production of aSGMKCs, as compared with the process of CIK cell production, previous studies have indicated the feasibility of producing large quantities of clinical-grade aSGMKCs (31-33).

Considering their functional similarities [including potent and non-MHC class I-restricted, NK and NK-like T-cell-mediated cytotoxic activity and a low potential of GvHD induction (20,34,35)], the present study aimed to compare aSGMKCs and CIK cells.

Materials and methods

Production of effector cells. Allogeneic SGMKCs were produced as previously described (34). Buffy coats of 35 healthy anonymous volunteer blood donors (purchased from the French National Blood Service following receipt of their written informed consent for research use of their blood donation) were used as a source of PBMCs. Buffy coats were obtained by centrifugation over a Ficoll layer (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) at 360 x g for 20 min at 20°C. PMBCs were activated with 10 ng/ml CD3 monoclonal antibody (mAb) Orthoclone OKT3 (OKT3; Janssen-Cilag, Levallois-Perret, France) and 500 IU/ml human interleukin-2 (IL-2; Proleukin; Novartis Pharmaceuticals Canada, Inc., Dorval, QC, Canada), and transduced on day 3 with the MP71-T34FT retroviral vector (Eufuts GmbH, Idar-Oberstein, Germany) encoding the truncated form of the human CD34 (selection marker) fused to the Herpes simplex virus thymidine kinase (HSV-tk) suicide gene (36) or the SFG.iCasp9.2A.ACD19 retroviral vector (provided by Professor M.K. Brenner, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA) encoding the human CD9 (selection marker) and the inducible caspase-9 (iCasp9) suicide gene (26). Cells were then immunomagnetically selected on day 5 with an autoMACS Pro Separator (Miltenyi Biotec SAS, Paris, France), based on the expression of the CD34 or CD19 membrane markers, and expanded until day 14. Transduced and CD34 or CD19-selected cells were referred to as aSGMKCs, while non-transduced cells that expanded in parallel for 14 days were termed control cells. The transduction efficiency (percentage of CD34 or CD19-positive cells following transduction) was 8.6±1.0% (n=13) and 51.2±6.1% (n=3), and the purity of the immunomagnetically selected fraction was 92.4±1.1% (n=13) and 94.8±0.4% (n=3) for CD34/HSV-tk and CD19/iCasp9-transduced cells, respectively. Relative cell growth was calculated as the ratio of the number of cells (counted using a B-500 microscope; Optika, Ponteferanca, Italy) of the indicated phenotype obtained at the end of the expansion at 37°C (day 14) to the input number of cells of the specific phenotype at initiation of the culture (day 0).

CTK cell production. The cells were produced according to three previously published protocols: Protocol 1 (P1), PBMC activation with 100 U/ml interferon-γ (IFN-γ; ProproTech, Inc., Neuilly-sur-Seine, France) at day 0 and 10 ng/ml OKT3 + 500 U/ml IL-2 at day 1 (9,37). These cells were referred to as CTK P1. Protocol 2 (P2), PBMC activation with 100 U/ml IFN-γ at day 0 and 10 ng/ml OKT3 + 500 U/ml IL-2 + 100 U/ml IL-1 (ProproTech, Inc.) at D0 (11,15). These cells were referred to as CTK P2. Protocol 3 (P3): PBMCs activation with 10 ng/ml OKT3 + 500 U/ml IL-2 + 20 ng/ml IL-7 (ProproTech, Inc.) + 20 ng/ml IL-15 (ProproTech, Inc.) at day 0 (38). These cells were referred to as CTK P3. All cells were expanded until day 14 in culture medium consisting in RPMI 1640 medium (Invitrogen; Thermo Fisher Scientific, Inc.) supplemented with 10% v/v human serum and 500 U/ml IL-2.

Flow cytometry. Effector cells were analyzed for the relative repartition of CD3+/CD56+ NK, CD3+/CD56- NK-like T and CD3-/CD56- T cells following staining with Pacific Blue-conjugated CD3 mAb (BD Biosciences, San Diego, CA, USA) and phycoerythrin-cyanin (PE-Cy)5-conjugated CD56 mAb (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). The purity of aSGMKCs was evaluated by flow cytometry following staining with PE-Cy7-conjugated mAb specific for CD34 or CD19 (BD Biosciences). Multi-color samples were acquired on a LSRII special order research product flow cytometer (LSRII; BD Biosciences) calibrated using a Cytometer Setup & Tracking Beads kit (BD Biosciences) to ensure consistency of fluorescence intensity measurement throughout all experiments. Compensation was
performed with a CompBeads kit (cat. no. 51-90-9001229; BD Biosciences). Cell debris and dead cells were excluded using forward scatter area and side scatter area and doublet cells were excluded using side scatter width and side scatter area. FACSDiva software (version 6.1.2; BD Biosciences) was used for the final analysis and graphical output.

In vitro cytotoxicity assay. Target cells (1,500 HeLa, Huh-7 cells/well, 2,500 SK-HeP1 cells/well, 20,000 PLC-PRF/5 cells/well; American Type Culture Collection, Molsheim, France) were co-cultured in RPMI 1640 medium (with 500 U/ml IL-2) in the presence or absence of graded quantities of effector cells for 6 days in flat bottom 96-well plates and, when indicated, in the presence of monoclonal mouse anti-human tumor necrosis factor-α (TNF-α; clone MAAb1; cat. no. 16-7348), monoclonal mouse anti-human IFN-γ (clone NIB42; cat. no. 16-7318), monoclonal mouse anti-human Fas-ligand (Fas-L; clone NOK-1; cat. no. 16-9919) or monoclonal mouse anti-human TRAIL (TRAIL clone RIK-2; cat. no. 16-9927) mAbs (5 µg/ml; eBiosciences, Inc., San Diego, CA, USA; 1:100).

Subsequently, non-adherent effector cells and dead target cells were removed by washing with phosphate-buffered saline (PBS), and the remaining viable, adherent target cells were stained with crystal violet (Sigma-Aldrich, St. Louis, MO, USA) at room temperature for 1 min. Absorbance was read at 560 nm on a Mithras LB940 microplate reader (Berthold Technologies GmbH & Co., Thoiry, France). Data are expressed as percentage killing, at the indicated effector:target (E:T) cell ratios as: [1 - (Abs_E:T / Abs_Ctrle)] x 100, where Abs.E:T indicates the absorbance at a given E:T ratio and Abs.Ctrle is the absorbance of target cells alone (E:T=0). Percentage killing is then expressed as lytic units 50% (LU50), calculated as the reverse of the number of cells per 10⁶ effector cells required to kill 50% of target cells (Fig. 1). LU50 of the experimental groups were normalized to the LU50 values of their control group, in order to normalize inter-experimental variations, and expressed as the mean ± standard error (20).

CD107a degranulation assay. Lymphokine-activated killer (LAK) cells were generated by activating PBMCs with IL-2 (1,000 U/ml) for 4 days. The effector cells (aSGMKCs or LAK cells) and target cells (Huh-7 cells or K562 cells, used as positive control of lysis) were co-incubated at 37°C in culture medium at an E:T cell ratio of 4:1 in the presence of monoclonal mouse anti-human PE-CD107a (cat. no. 555801) or isotype control antibody (10 µl per 10⁶ effector cells; BD Biosciences; 1:10) to a total volume of 100 µl in a flat bottom 96-well plate. After 1 h, 50 µl culture medium containing brefeldin A (10 µg/ml) and GolgiStop (4 µl for 6x10⁶ cells; BD Biosciences) were added for a further 3 h incubation. The effector cells were then labeled in cytometry tubes with Pacific Blue-conjugated CD3 mAb and PE-Cy5-conjugated CD56 mAb, washed twice with 3 ml PBS (Invitrogen; Thermo Fisher Scientific, Inc.), fixed with PBS supplemented with 2% v/v formaldehyde (Merck Millipore, Darmstadt, Germany), and analyzed by flow cytometry (LSRII).

Ethical approval. Animal experiments were performed following approval by the local ethical committee (Comité Régional d’Ethique en Matière d’Expérimentation Animale de Strasbourg; approval no. AL/34/41/02/13) on November 7, 2012, according to European guidelines (directive 2010/63/UE) and relevant national rules. For ethical reasons, mice were not monitored until tumor-associated mortality but were sacrificed at the end of experiments by cervical dislocation following general anesthesia with 3% isoflurane.

In vivo cytotoxicity assays. In vivo cytotoxicity assays were performed as previously described (20). Luciferase-expressing Huh-7 target cells (1x10⁶ Huh-7-Luc cells) were subcutaneously co-injected into the right flank of 86 severe combined immunodeficient-beige (SCIB-bg) recipient mice (Taconic Biosciences, Inc., Ejby, Denmark) in the absence (PBS, n=13) or presence of 10x10⁶ iCasp9-expressing aSGMKCs effector cells (C1K P1, n=14; C1K P2, n=17; C1K P3, n=13; iCasp9-expressing aSGMKCs, n=17). Daily intraperitoneal injections of IL-2 (10⁶ IU/kg) were administered throughout the duration of the experiment. When indicated, an intraperitoneal injection of the iCasp9 prodrug [AP20187; also termed chemical inducer of death (CID); Clontech Laboratories, Saint Germain en Laye, France] at 2.5 mg/kg was performed together with the aSGMKCs injection (n=12). Eight-to-twelve week-old male and female mice were used and randomly distributed in experimental groups. The mice were housed under specific pathogen-free conditions with food and drinking water containing 1 mg/ml paracetamol (Doliprane 300; Sanofi-Aventis, Paris, France) ad libitum. Luciferase activity of Huh-7-Luc cells, determined by bioluminescence imaging (BLI) using an IVIS Lumina Series II camera (PerkinElmer, Roissy, France) following an intraperitoneal injection of 100 µl luciferin (20 mg/ml; Caliper Lifesciences), was determined at the time of target cell injection on days 0, 4, 7, 11 and 14. Tumor cell bioluminescence, analyzed with Living Image software (version 3.1; PerkinElmer), was quantified in a round-shape...
region of interest centered on the cell injection site and was expressed as photons/sec/cm²/steradian (p/sec/cm²/sr). Relative tumor growth was obtained by calculating the ratio of bioluminescence at the indicated day to the bioluminescence at day 0. A relative tumor growth value of ≤1 indicated tumor cell elimination and a value of >1 indicated an expansion of tumor cells.

Statistical analysis. Data that was not normally distributed was compared with Mann-Whitney U or Fisher’s exact non-parametric tests; when data distribution was normal, Student’s paired t-test was used. Data are expressed as the mean ± standard error. A χ² test was performed to compare the number of animals with and without relapse in the experimental groups compared with the control group. P<0.05 indicates a statistically significant difference.

Results

Phenotypic characterization of aSGMKCs. As previously reported (20,35), aSGMKCs were predominantly constituted of CD3⁺CD56⁻ T cells, then by CD3⁺CD56⁻ NK-like T cells and to a lesser extent by CD3⁻CD56⁺ NK cells. Other mononuclear subsets, including B cells or monocytes, were not detectable (Fig. 2A). This repartition was similar to the one observed in non-transduced control cells that were activated and expanded in parallel with aSGMKCs (Fig. 2A). This indicates that the cell culture process was responsible for these phenotypical modifications and that the gene transfer process did not lead to the preferential transduction or selection of a lymphocyte population. Furthermore, the ex vivo expansion was associated with a significantly higher relative expansion of NK-like T cells than that observed with NK or T cells (P<0.05; Student’s paired t-test; Fig. 2B).

Mechanism of aSGMKC-mediated killing of hepatoma cells. As previously reported, aSGMKCs may provide a potent cytotoxic activity toward various liver-derived cell lines, such as Huh-7, PLC-PRF5 (HCC cell lines) and SK-Hep1, and toward the cervical carcinoma cell line HeLa (20). The cytotoxic activity of aSGMKCs, evaluated at different E:T ratios, indicated that 50 and 90% target cell killing were obtained at mean E:T ratios of ~3:1 and ~13:1 to 40:1, respectively (Fig. 3A), excluding PLC-PRF5 cells, which were more sensitive to aSGMKC-mediated killing. It was previously reported that the cytotoxic activity of aSGMKCs, evaluated in more detail toward Huh-7 cells, was HLA class-I independent and was predominantly mediated by CD56⁺/CD3⁺ NK and CD56⁺/CD3⁻ NK-like T cells (20). In order to further characterize the mechanisms of target cell killing, the involvement of the granzyme/perforin pathway was evaluated by CD107a staining of aSGMKCs (and of LAK cells, used as a positive control of non-MHC-restricted cytotoxic cells) following incubation with Huh-7 cells (or K562 cells, used as a control of LAK-sensitive target cells). Following co-incubation with Huh-7 cells, the frequency of CD107a-positive cells, corresponding to effector cells with degranulated lytic granules, were higher in LAK cells than in aSGMKCs generated from the specific donors (Fig. 3B). A similar trend was observed, to a greater extent, when effector cells were incubated with K562 cells (Fig. 3B). Regardless of the E:T cell combinations, the frequency of CD107a-positive cells was higher in the NK cell subset than in the NK-like T cell subset, while no induction of CD107a expression was observed in T cells (Fig. 3C). Overall, considering that the frequency of NK and NK-like T cells was lower than that of T cells (Fig. 2A), the induction of CD107a expression in aSGMKCs following incubation with Huh-7 cells was minimal, suggesting that other killing mechanisms may be involved.

Thus, in vitro cytotoxicity assays were performed in the presence or absence of antibodies targeting IFN-γ, TNF-α, Fas-L or TRAIL. The cytotoxic activity of aSGMKCs was not affected by the addition of anti-IFN-γ or anti-TNF-α antibodies alone but a significant (P<0.05; Mann-Whitney U test; Fig. 3D) reduction of the cytotoxicity level was observed when both antibodies were added, suggesting a synergistic involvement of IFN-γ and TNF-α in target cell killing. TRAIL-mediated killing was also involved in aSGMKC-induced killing, as demonstrated by the significant (P<0.05; Mann-Whitney U test; Fig. 3D) inhibitory effect of blocking anti-TRAIL antibodies on the cytotoxicity level. Blocking anti-Fas-L antibodies had no significant inhibitory effect on sSGMKCs cytotoxicity but enhanced the reduction of cytotoxicity by anti-TRAIL antibodies (P<0.05; Fig. 3D).
Allogeneic SGMKCs are phenotypically and functionally similar to CIK cells. It was previously reported, that aSGMKCs exhibited reduced in vitro and in vivo alloreactivity (20,34,35), in terms of proliferative response and potential of GvHD induction and that their cytotoxicity was non-MHC class I-restricted and predominantly

Figure 3. Characterization of aSGMKC cytotoxic activity. (A) Cytotoxic activity of aSGMKCs tested at different effector:target ratios against HCC cell lines (Huh-7, PLC-PRF5) and non-HCC cell lines (HeLa, SK-Hep1). Data are expressed as mean ± standard error of 6 independent experiments. (B) Percent of CD107a-positive cells in aSGMKCs and LAK cells after a 4 h-culture in the absence (NS) or presence of Huh-7 or K562 target cells. Data are expressed as mean ± standard error of 3 independent experiments. (C) Percent of CD107a-positive cells gated in NK, NK-like T and T cell subsets in the experiments reported in B. (D) Cytotoxic activity of aSGMKCs incubated with Huh-7 cells in the absence or presence of blocking monoclonal antibodies against IFN-γ, TNF-α, Fas-L or TRAIL. Data are expressed as normalized LU50 (mean ± standard error) of 7 independent experiments. Control group: 100%=587±286 LU50 (*P<0.05 vs. control). aSGMKCs, allogeneic suicide gene-modified killer cells; HCC, hepatocellular carcinoma; LAK, lymphokine-activated killer; NK, natural killer; IFN-γ, interferon-γ; TNF-α, anti-tumor necrosis factor-α; Fas-L, fas ligand; TRAIL, TNF-related apoptosis inducing ligand; LU50, lytic units 50%.

Figure 4. Comparison of aSGMKCs and CIK cells produced according to three different protocols (P1-P3). (A) Frequency of NK (white bars), NK-like T and T cells in aSGMKCs, CIK cells and PBMCs. In a single experiment, aSGMKCs, CIK cells and PBMCs were isolated and produced from the same healthy donor. Data are expressed as the mean of four independent experiments. (B) Cytotoxic activity of aSGMKCs and CIK cells evaluated after day 1 or 6 of co-culture with HeLa and Huh-7 target cells. Data are expressed as normalized LU50 (mean ± standard error) of five independent experiments. Control groups (aSGMKCs): 100%=258±137 LU50 (HeLa, day 1), 752±362 LU50 (HeLa, day 6), 90±28 LU50 (Huh-7, day 1) and 162±53 LU50 (Huh-7, day 6) (*P<0.05 vs. aSGMKCs). aSGMKCs, allogeneic suicide gene-modified killer cells; CIK, cytokine-induced killer; P1/2/3, protocol 1/2/3; NK, natural killer; PBMCs, peripheral blood mononuclear cells; LU50, lytic units 50%.
mediated by NK and NK-like T cells (20). Together with the present observations indicating the involvement of TRAIL in the killing mechanism, this prompted the evaluation of similarities between aSGMKCs and CIK cells, another immunotherapy product identified to provide potent non-MHC class I-restricted anti-tumor activity toward hematologic and solid tumors. Indeed, CIK cells have also previously exhibited NK and NK-like T cell-mediated cytotoxicity and low potential of GvHD induction (39). Thus, the phenotypic and cytotoxic activity of aSGMKCs and CIK cells were compared, generated in parallel from the same healthy donors using three different cell expansion protocols for CIK cell production. There were no significant differences between aSGMKCs and CIK cells in terms of repartition of T, NK-like T and NK cell subsets (Fig. 4A). Furthermore, the cytotoxic activity of aSGMKCs, evaluated against Huh-7 cells (or HeLa cells, used as a positive control of target cell killing) was similar, or even greater than that of CIK cells, when evaluated following 1 or 6 days of E:T cell co-culture (Fig. 4B).

In vivo anti-tumor effect of aSGMKCs toward hepatoma cells. The data presented was generated using aSGMKCs transduced with an HSV-tk-expressing retroviral vector. However, a new generation of suicide genes, based on the inducible activation of caspase domains, has been recently developed, including the iCasp9 gene (40), whose efficacy has been demonstrated in clinical trials (26,27). This transgene inducible activation of caspase domains, has been recently developed, including the iCasp9 gene (40), whose efficacy has been demonstrated in clinical trials (26,27). This transgene induces rapid killing of aSGMKCs in the presence of their prodrug, CID, as >95% of cells are killed within 2 h, as determined by flow cytometry following Annexin V/propidium iodide staining (unpublished data). This is more rapid than the killing of HSV-tk-expressing aSGMKCs by its prodrug, ganciclovir (20,41). Therefore, iCasp9-expressing aSGMKCs were compared with CIK cells using an in vivo cytotoxicity assay. Immunodeficient SCID-bg mice were subcutaneously injected with Huh-7-Luc target cells, in the absence or presence of aSGMKCs or CIK cells, and monitored for tumor growth by BLI. Fig. 5 represents the data obtained for one representative mouse of each group.

When Huh-7-Luc cells were injected alone, the median relative tumor growth was >1 at all time points, indicating the expansion of tumor cells (Table I). When CIK cells were co-injected with target cells, the median relative tumor growth values were <1 (P<0.05, Mann-Whitney U test), indicating that CIK cells exhibited a significant antitumor effect. When aSGMKCs were co-injected with target cells, a similar anti-tumor effect was also observed (P<0.05, Mann-Whitney U test). Notably, the antitumor effect of aSGMKCs was reversed by CID administration, confirming that the effect was aSGMKC-mediated (Table I). However, tumor escape occurred in certain (12-38%) mice injected with aSGMKCs or CIK cells. Therefore, the frequency of mice with tumor regression (a relative tumor growth value <1) was also evaluated. As indicated by Table I, this frequency was 23.1% in the control group injected with Huh-7-Luc cells alone, indicating a lack of engraftment in these mice. However, this frequency significantly (P<0.05, χ2 test) increased to 61.5‑88.2% of mice injected with aSGMKCs or CIK cells, indicating tumor rejection in these groups. It is of note that the frequency reversed to 25.0% in mice receiving aSGMKCs when the prodrug CID was administered at the same time (Table I), indicating that aSGMKCs were rapidly killed, before having time to exert their anti-tumor effects.

### Table I. Effect of varied treatments on tumor growth.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Day 0 (min-max)</th>
<th>Day 4 (min-max)</th>
<th>Day 7 (min-max)</th>
<th>Day 11 (min-max)</th>
<th>Day 14 (min-max)</th>
<th>Regressing tumors%</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBS (n=13)</td>
<td>1.0 (1.0-1.0)</td>
<td>2.2 (0.1-290.6)</td>
<td>5.9 (0.1-440.5)</td>
<td>27.8 (0.1-1231.0)</td>
<td>33.3 (0.0-1739.3)</td>
<td>23.1</td>
</tr>
<tr>
<td>CIK P1 (n=14)</td>
<td>1.0 (1.0-1.0)</td>
<td>0.1c (0.0-22.9)</td>
<td>0.3c (0.0-21.5)</td>
<td>0.2c (0.0-46.2)</td>
<td>0.3c (0.0-104.6)</td>
<td>71.4d</td>
</tr>
<tr>
<td>CIK P2 (n=17)</td>
<td>1.0 (1.0-1.0)</td>
<td>0.1c (0.0-22.5)</td>
<td>0.1c (0.0-193.2)</td>
<td>0.1c (0.0-297.6)</td>
<td>0.1c (0.0-137.2)</td>
<td>88.2d</td>
</tr>
<tr>
<td>CIK P3 (n=13)</td>
<td>1.0 (1.0-1.0)</td>
<td>0.1c (0.0-1.0)</td>
<td>0.1c (0.0-1.4)</td>
<td>0.1c (0.0-26.4)</td>
<td>0.1c (0.0-26.0)</td>
<td>61.5d</td>
</tr>
<tr>
<td>SGMKC (n=17)</td>
<td>1.0 (1.0-1.0)</td>
<td>0.1c (0.0-16.0)</td>
<td>0.1c (0.0-41.8)</td>
<td>0.1c (0.0-109.9)</td>
<td>0.1c (0.0-110.4)</td>
<td>76.5d</td>
</tr>
<tr>
<td>SGMKC + CID (n=12)</td>
<td>1.0 (1.0-1.0)</td>
<td>0.8 (0.1-114.7)</td>
<td>1.4 (0.0-97.2)</td>
<td>0.3 (0.0-136.2)</td>
<td>0.7 (0.0-330.7)</td>
<td>25.0</td>
</tr>
</tbody>
</table>

aRelative tumor growth represents the ratio of the luciferase activity at the indicated days to the initial luciferase activity at day 0. A relative tumor growth value of <1 (dashed line) indicates tumor cell elimination by effector cells, while a value of >1 indicates an expansion of tumor cells. Results are pooled data of three independent experiments. bFrequency of mice with tumor regression, i.e. (number of mice with a relative tumor growth value of <1 / total number of mice) x 100, at day 14. cP<0.05 vs. PBS (Mann-Whitney U test). dP<0.05 vs. PBS (χ2 test, comparing the number of mice with relative tumor growth of <1 vs. the number of mice with relative tumor growth>1). PBS, phosphate-buffered saline; CIK, cytokine-induced killer; P1/2/3, protocol 1/2/3; SGMKC, suicide gene-modified killer cells; CID, chemical inducer of death.
Discussion

A previous study demonstrated (20) that aSGMKCs produced following CD3 plus IL-2 activation, a combination previously described (31) and used in our clinical trial of aSGMKC infusion at time of bone marrow transplantation (24), exhibit a potent non-MHC class I-restricted cytotoxic activity towards HCC cell lines that is mediated primarily by NK and NK-like T cells. Numerous studies have indicated that ex vivo-activated autologous PBMCs, previously expanded in similar conditions as the current aSGMKCs [namely CIK cells (3,5)], however without gene transfer, exhibit phenotypic and functional properties similar to those of the current aSGMKCs, including high cytotoxic activity (6), particularly against HCC cell lines (4,5), and low potential for GvHD induction (7,8). The cytotoxic activity of CIK cells is non-MHC-restricted and is primarily mediated by NK-like T cells (3). To the best of our knowledge, the current study is the first to indicate that, by comparing cells expanded according to protocols used for aSGMKC and CIK cell production, aSGMKCs are suicide-gene-modified CIK cells. The repartition of NK, NK-like T and T cells within aSGMKCs is similar to that observed in CIK cells, and the in vitro and in vivo cytotoxic activity of aSGMKCs is as potent as that obtained with CIK cells. Although further experiments are required, the results of the present study suggest that the association between IFN-γ, TNF-α and TRAIL, possibly in synergy with Fas-L, all previously demonstrated to be involved in CIK-mediated cell killing, may be involved as an effector mechanism of aSGMKC-induced target cell killing (42-44). Overall, the current results support the hypothesis that aSGMKCs, proposed to be used clinically in an allogeneic setting, are similar to CIK cells, which are currently used clinically in an autologous setting.

Various clinical studies (11-18), several of which were randomized (15-18), comparing TACE, RFA and/or surgery with or without CIK therapy, have demonstrated the ability of this autologous adoptive immunotherapy to reduce HCC recurrence and to increase median time to relapse, relapse-free survival, and overall survival in patients with HCC. These clinical results strengthen the hypothesis that aSGMKCs may exert an anti-tumor effect against HCC, particularly as they are allogeneic; the MHC-restricted and/or non-MHC-restricted alloreactivity of aSGMKCs may provide an additional mechanism for tumor recognition.

Another issue to consider for aSGMKC-based adoptive allogeneic immunotherapy is alloimmunization. As the patients are immunocompetent, an anti-aSGMKC immune response leading to aSGMKC rejection should occur. This is an additional safety element that would limit the risk of long-term aSGMKC toxicity, but it may also limit short-term anti-tumor efficacy. This means that aSGMKCs must be sufficiently cytotoxic to operate quickly and destroy tumor cells prior to being rejected by the patient's immune system. The observations of the current study indicate that high cytotoxic activity in aSGMKCs may be detected within 1 day in vitro and 4 days in vivo (prior to the development of an immune response).
response leading to their rejection). In phase I/II clinical trials of infusion of partially HLA-matched EBV-specific allogeneic T cells for the treatment of post-transplant EBV-induced lymphoma, performed by Haque et al (45,46) infused cells may be detected for up to 44 days following infusion (45), with patients experiencing withdrawal or reduction of immunosuppression for the previous 2-6 weeks. However, in vivo survival was typically limited to ~1 week. In the phase II study reported by Haque et al (46) complete responses were observed in 14 out of 33 patients despite alloimmunization, indicating that alloimmunization may not represent a strong limitation to adoptive allogeneic immunotherapy if short-term anti-tumor effects are selected. Similarly, Slavin et al (47) performed a phase I trial investigating the infusion of ‘intentionally HLA-mismatched IL-2 activated killer’ (IMAK) cells produced from normal donors to patients with solid tumors. Rejection of infused IMAK cells was expected to occur within 1 week and was considered a safety mechanism to avoid GVHD. Infusion of IMAK cells was determined to be safe and, among the 35 patients with metastatic solid tumors, only one grade I GVHD was observed.

Taking advantage of the resistance of aSGMKCs to calcineurin inhibitors, such as cyclosporin A and FK506 (20,48,49), it was previously reported in a surrogate mouse model of aSGMKCs that alloimmunization of such effector cells may be prevented in immunocompetent mice, leading to an anti-tumor effect toward a syngeneic HCC cell line (20). However, other methods for preventing alloimmunization should be considered by eliminating or inhibiting regulatory T cells, using cyclophosphamide or fludarabine-based lymphodepletion protocols (50,51) [as performed by Slavin et al (47) at the time of IMAK infusion] or mTOR inhibitors such as rapamycin [known to also exhibit anti-tumor activity (52,53)]. Induction of aSGMKC-specific tolerance by co-infusion of non-depleting CD3 or CD4 monoclonal antibodies (54,55) or by administration of CTLA4-Ig (56) may also be considered.

In conclusion, the present study has demonstrated that aSGMKCs are CIK cells with a high cytotoxic activity towards solid tumors. Therefore, the production of a bank of ‘ready-to-use’ aSGMKCs for the treatment of solid tumors, particularly for indications of hepatic localization, should be considered. Additionally, their advantages include rapid availability and low potential for GVHD induction, as well as the fact that no clinical batch in the bank may be lost due to last-minute contra-indication from the recipient. To prevent secondary effects leading to toxicity, the suicide gene will allow the specific elimination of aSGMKCs through the administration of the prodrug. The primary issue remaining to be determined is the clinical efficacy of aSGMKCs in immunocompetent animal HCC models, provided that alloimmunization may be controlled by an immunosuppressive and/or lympho-ablative conditioning regimen.

Acknowledgements

The authors would like to thank Mr. Nicolas Brignon and Mr. Richard Pil of their excellent animal care. This study was supported by Inserm, the Fondation pour la Recherche Médicale (Comité Alsace), the Ligue Nationale Contre le Cancer (Conférence de Coordination Inter-Régionale Grand-Est; grant no. 1F11005LBBKD), the Association pour la recherche sur le Cancer (ARC; grant no. SF120111203529). Dr Eric Robinet was supported by the Agence Nationale pour la recherche sur le SIDA et les Hépatites Virales (grant no 2008 059 ULP), Dr Tao Wu was a recipient of a fellowship of the Alsace Region and Dr Céline Leboeuf was a recipient of fellowships of the Fondation Transplantation and the ARC (grant no. DOC2010603384).

References


